GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biocure Technology Inc (XCNQ:CURE) » Definitions » Quick Ratio

Biocure Technology (XCNQ:CURE) Quick Ratio : 0.04 (As of Mar. 2024)


View and export this data going back to 2010. Start your Free Trial

What is Biocure Technology Quick Ratio?

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Biocure Technology's quick ratio for the quarter that ended in Mar. 2024 was 0.04.

Biocure Technology has a quick ratio of 0.04. It indicates that the company cannot currently fully pay back its current liabilities.

The historical rank and industry rank for Biocure Technology's Quick Ratio or its related term are showing as below:

XCNQ:CURE' s Quick Ratio Range Over the Past 10 Years
Min: 0.01   Med: 0.1   Max: 1.33
Current: 0.04

During the past 13 years, Biocure Technology's highest Quick Ratio was 1.33. The lowest was 0.01. And the median was 0.10.

XCNQ:CURE's Quick Ratio is not ranked
in the Biotechnology industry.
Industry Median: 3.6 vs XCNQ:CURE: 0.04

Biocure Technology Quick Ratio Historical Data

The historical data trend for Biocure Technology's Quick Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biocure Technology Quick Ratio Chart

Biocure Technology Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Quick Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.10 0.03 0.57 0.03 0.03

Biocure Technology Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Quick Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.02 0.82 0.80 0.03 0.04

Competitive Comparison of Biocure Technology's Quick Ratio

For the Biotechnology subindustry, Biocure Technology's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biocure Technology's Quick Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biocure Technology's Quick Ratio distribution charts can be found below:

* The bar in red indicates where Biocure Technology's Quick Ratio falls into.



Biocure Technology Quick Ratio Calculation

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.

Biocure Technology's Quick Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Quick Ratio (A: Dec. 2023 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(0.011-0)/0.331
=0.03

Biocure Technology's Quick Ratio for the quarter that ended in Mar. 2024 is calculated as

Quick Ratio (Q: Mar. 2024 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(0.013-0)/0.356
=0.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biocure Technology  (XCNQ:CURE) Quick Ratio Explanation

The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.

In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.

The higher the quick ratio, the better the company's liquidity position.


Biocure Technology Quick Ratio Related Terms

Thank you for viewing the detailed overview of Biocure Technology's Quick Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Biocure Technology (XCNQ:CURE) Business Description

Traded in Other Exchanges
N/A
Address
1055 West Hastings Street, Suite 300, Vancouver, BC, CAN, V6E 2E9
Biocure Technology Inc is a South Korean-based Bio-Pharmaceutical company specializing in the development and potential commercialization of biosimilar pharmaceutical products. It is in the process of preclinical trials of five majorly biosimilar products in South Korea, including Interferon Beta 1b, PEGFilgrastim, and Ranibizumab as well as CAR-T Cell Therapy. Interferon Beta 1b is used for treating relapsing forms of multiple sclerosis Filgrastim is used to treat neutropenia, a lack of certain white blood cells caused by bone marrow transplants, chemotherapy, and other conditions. Ranibizumab is used for treating macular degeneration. It is also used to treat a type of eye problem known as macular edema, as well as certain eye problems caused by diabetes.

Biocure Technology (XCNQ:CURE) Headlines